

# DRUG PRIOR AUTHORIZATION COMMITTEE

*June 17, 2010*

## TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Henry Petry, Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:30	Pharmacy Program/ Budget Update	George L. Oestreich/ Andrew Haslag
11:30 - 11:35	DUR Update	Tisha McGowan

### Old Business

11:35 - 11:45	a. <b>Implementation Schedule</b> (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver
---------------	--	---------------

### New Business

11:45 – 12:15	New Drug/Product Reviews	
	a. <b>Proposed Actions</b> (See website and Attached Summary)	
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Products	
	iv. Prior Authorization	
	b. <b>Clinical Edits</b>	
	i. <b>Psychotropic Edit Discussion</b>	
	• Discussion	
	• Public Hearing	
	• Decision	

12:15-1:30	<i>Proposed New Program Actions of Existing Products</i>	
------------	--	--

- |  |  |
|--|--|
| a. <b><u>Drug List (PDL)</u></b>                           |  |
| i. <b>Beta Blockers</b>                                    |  |
| • Discussion   |  |
| • Public Hearing   |  |
| • Decision   |  |
| ii. <b>Calcium Channel Blockers/Dihydropyridines</b>       |  |
| • Discussion   |  |
| • Public Hearing   |  |
| • Decision   |  |
| iii. <b>Calcium Channel Blockers/ Non-Dihydropyridines</b> |  |
| • Discussion   |  |
| • Public Hearing   |  |
| • Decision   |  |
| iv. <b>Calcium Channel Blocker/ARB Combinations</b>        |  |
| • Discussion   |  |
| • Public Hearing   |  |
| • Decision   |  |
| v. <b>Cox II Inhibitors</b>                                |  |
| • Discussion   |  |
| • Public Hearing   |  |
| • Decision   |  |
| vi. <b>Hepatitis C Agents</b>                              |  |
| • Discussion   |  |
| • Public Hearing   |  |
| • Decision   |  |
| vii. <b>Amylin Analogs</b>                                 |  |
| • Discussion   |  |
| • Public Hearing   |  |
| • Decision   |  |
| viii. <b>GLP -1 Receptor Agonists</b>                      |  |
| • Discussion   |  |
| • Public Hearing   |  |
| • Decision   |  |

- ix. **DPP-IV Inhibitors**
    - Discussion
    - Public Hearing
    - Decision
  - x. **Onychomycosis Antifungals**
    - Discussion
    - Public Hearing
    - Decision
  - xi. **Proton Pump Inhibitors**
    - Discussion
    - Public Hearing
    - Decision
  - xii. **Ribavirins**
    - Discussion
    - Public Hearing
    - Decision
  - xiii. **Topical Immunomodulators**
    - Discussion
    - Public Hearing
    - Decision
  - xlv. **Topical Androgen Agents**
    - Discussion
    - Public Hearing
    - Decision
- c. **Preferred Drug List**
- i. Process discussion or questions
  - ii. Therapeutic classes-to be *announced at meeting*

1:30

**LUNCH**

1:45-2:00

**Program Utilization Information**

2:00-2:30

**Other Business**

- i. *Top 25" Drugs by Cost*
- ii. *Clinical Edit Summary Report*
- iii. *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda.  
Times noted are approximate, Agenda may move more quickly*

**Executive Session**

2:30-2:35	Minutes Review	Discussion/Approval
2:35-3:00	Case Reviews	Rhonda Driver/ Jenna Twehus

**NEXT MEETING: September 16, 2010 – 205 Jefferson Street, 10<sup>th</sup> Floor**